Answers are grounded in this paper and cite their sources.
Introduction The adoption of intensive lipid-lowering strategies after ACS must balance proven efficacy with muscular/hepatic tolerability and early clinical safety, particularly in populations with specific genetic and metabolic backgrounds, such as in North Africa. Objective To evaluate and compare the short-term safety and clinical event profiles of three intensive lipid-lowering regimens in a real-world Tunisian cohort during the high-risk phase following an ACS. Method This prospective, randomized, single-center study was conducted in the Cardiology Department of Mohamed Ben Sassi University Hospital, Gabès, Tunisia, from January to December 2024. A total of 120 patients with confirmed ACS (mean age 60.5 years, 69.2% male) were randomized into three therapeutic groups of 40 patients each: Group 1: atorvastatin 80 mg + Ezetimibe 10 mg; Group 2: atorvastatin 40 mg + ezetimibe 10 mg; Group 3: atorvastatin 80 mg alone. Treatment was initiated during hospitalization. We systematically collected data on adverse events (myalgia, hepatic cytolysis [ASAT/ALAT > 3 × ULN], rhabdomyolysis) and major clinical outcomes (all-cause death, myocardial infarction [MI], stroke, hospitalization for heart failure [HF]) over the follow-up period. Between-group comparisons were performed using appropriate non-parametric tests. Results In the overall cohort, the incidence of adverse events and clinical outcomes was low and did not differ significantly between groups, as summarized on Figure 1 . Myalgia was reported in 11.7% (14/120) and hepatic cytolysis in 5.0% (6/120), with all cases being mild and transient (< 3 × ULN). No case of rhabdomyolysis or stroke occurred. Clinical events included all-cause death in 3.3% (4/120), MI in 5.0% (6/120), and HF hospitalization in 5.0% (6/120). The composite MACE rate (death/MI/stroke) was 5.8% (7/120). No statistically significant differences in the incidence of myalgia, cytolysis, death, MI, or HF hospitalization were observed between the three treatment groups (all P > 0.05). Conclusion In this Tunisian ACS cohort, all intensive lipid-lowering regimens showed comparable short-term safety, with no excess muscular, hepatic, or cardiovascular risk. The superior efficacy of upfront combination therapy thus comes without a safety trade-off, supporting its early use.
No takes yet. Share an insight, caveat, or question.
Touati et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: